ClinicalTrials.gg
CompletedNCT02052752Updated May 18, 2015Results posted

A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions

A Phase 4 interventional study of 3% Benzoyl Peroxide and 3% Benzoyl Peroxide Placebo in Skin Diseases, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 12 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-05-18.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
12 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 202 studies in Skin Diseases with a site in United States — 32 open to participants now, 49 under way, 9 of them phase 3. Skin Diseases · United States.

Enrollment
88th of 172
90 · median 99
Started
2014
with 2 others
Phase 4
8 of 202
none open now
Registered
57th of 202
by date

Among the 202 studies in Skin Diseases with a site in United States, this one is the 88th largest by enrollment of the 172 interventional ones that give a count, is one of 3 that started in 2014, is one of 8 in phase 4, and was the 57th registered.

Skin Diseases

496 studies on the registry are indexed under Skin Diseases; 78 are open to participants now.

Browse Skin Diseases studies →

Open to participants now

32 of the 202 studies in Skin Diseases with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 12 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies in Skin Diseases with a site in United States, or all of them as a file.
02

Study summary

5 Day study to assess how quickly a topical acne product begins to work.

03

Conditions studied

  • Skin Diseases

Browse trials for

04

Who can participate

Ages eligible
12 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of understanding and willing to provide signed and dated written voluntary (and any local or national authorization requirements) before any protocol specific procedures are performed.
  2. Fitzpatrick Skin Type I - V.
  3. Male or female aged from 12 to 45 years, inclusive, at time of consent.
  4. Mild to moderate facial acne vulgaris as determined by the Investigator, with a minimum of 10 inflammatory lesions (papules plus pustules, including nasal lesions) and a minimum of 10 non-inflammatory lesions (open and closed comedones, including nasal lesions).
  5. Three appropriate and evaluable target lesions, as judged by the Investigator.
  6. Able to complete the study and to comply with study instructions.
  7. Sexually active females of participating in the study must agree to use a medically acceptable method of while receiving protocol-assigned product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses. Acceptable contraceptive methods include the following:

    • Hormonal contraception, including oral, injectable, or implantable methods started at least 2 months prior to screening. If hormonal contraception was started less than 2 months prior to screening, then a form of nonhormonal contraception should be added until the third continuous month of hormonal contraception has been completed.
    • Two forms of reliable nonhormonal contraception, to include the use of either an intrauterine device plus a reliable barrier method or 2 reliable barrier methods. Reliable barrier methods include condoms or diaphragms. A cervical cap is also a reliable barrier method, provided that the female participant has never given birth naturally. The combined use of a condom and spermicide constitute 2 forms of acceptable nonhormonal contraception, provided that they are both used properly. The use of spermicide alone and the improper use of condoms are inferior methods of contraception. Participants with surgical sterilization, including tubal sterilization or partner's vasectomy, must use a form of nonhormonal contraception. A barrier method or sterilization plus spermicide is acceptable.
    • Women who are not currently sexually active must agree to use a medically accepted method of contraception should they become sexually active while participating in the study.

Exclusion criteria

Exclusion Criteria:

  1. Has any nodulocystic lesions at the baseline evaluation.
  2. Female who is pregnant, trying to become pregnant, or breastfeeding.
  3. Has active or chronic skin allergies.
  4. Has a history of acute or chronic disease that might interfere with or increase the risk of study participation.
  5. Had skin cancer treatment in preceding 12 months.
  6. Has damaged skin on facial areas (e.g., sunburn, tattoo, or scar).
  7. Had any medical procedure (e.g., laser resurfacing, chemical peel, or plastic surgery) on facial areas in preceding 12 months.
  8. Had any cosmetic procedure (e.g., microdermabrasion) on facial areas within 8 weeks of the baseline visit.
  9. Has any dermatological disorder that in the opinion of the Investigator may interfere with the accurate evaluation of the participant's facial appearance.
  10. Received any drug or procedure within 28 days of study day 1 or is scheduled to receive an investigational drug (other than the study products) or procedure during the study.
  11. Currently using any medication that in the opinion of the Investigator may affect the evaluation of the study products or place the participant at undue risk.
  12. Has a history of known or suspected intolerance to any of the ingredients of the study products (i.e., benzoyl peroxide).
  13. Considered unable or unlikely to attend the necessary visits.
  14. Has used non-steroidal anti-inflammatory drugs for the treatment of acne or for treatment durations longer than 7 days for any condition.
  15. Uses oil-based sunscreens or sunscreens containing active ingredients that may have an effect on acne.
  16. Has received treatment with estrogens (including oral, implanted, and topical ), androgens, or anti-androgenic agents for 12 weeks or less immediately prior to starting application of the study product. Participants who have been treated with estrogens, as described above, androgens, or anti-androgenic agents for more than 12 consecutive weeks prior to starting application of the study product are allowed to enroll as long as they do not expect to change dose, drug, or discontinue use during the study.
  17. Has used topical antibiotics on the face or use of systemic antibiotics within the previous 2 weeks.
  18. Has used topical anti-acne medications (e.g., BPO, azelaic acid, resorcinol, salicylates) within the previous 2 weeks.
  19. Has used topical on the face or systemic corticosteroids within the previous 4 weeks. Use of inhaled, intra-articular or intra-lesional steroids other than for facial acne is acceptable.
  20. Has used systemic retinoids within the previous 6 months or topical retinoids within the previous 6 weeks.
  21. Uses abradants, facials, peels containing glycolic or other acids; masks, washes or soaps containing BPO, salicylic acid, or sulfacetamide sodium; non-mild facial cleansers, or moisturizers that contain retinol, salicylic acid or α- or β-hydroxy acids.
  22. Uses medications known to exacerbate acne (e.g., mega-doses of vitamin D [>2000 IU/day] and vitamin B12 [>1 mg/day]; systemic steroids; androgens; haloperidol; halogens such as iodide and bromide; lithium; hydantoin; and phenobarbital).
  23. Has had any facial procedure (e.g., blue light, chemical or laser peel, microdermabrasion) performed by any practitioner within 4 weeks before the study started or during the course of the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Test Product

    Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.

    Drug: 3% Benzoyl Peroxide

  • Active comparator
    Vehicle gel

    The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.

    Drug: 3% Benzoyl Peroxide Placebo

  • Placebo comparator
    Positive control

    A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.

    Drug: Neutrogena Rapid Clear®

Interventions

  • Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.

  • Drug3% Benzoyl Peroxide Placebo

    The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.

  • DrugNeutrogena Rapid Clear®

    A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.

06

What researchers measure

Primary outcomes

  1. To Assess the Percentage Change in Acne Lesion Swelling (Height) of the Target Lesion for 3% Benzoyl Peroxide (BPO) Gel Test Product Relative to the Vehicle Gel After 4 Once-daily Applications.

    The Investigator assessed and score each target lesion's swelling (elevation), elevation scores were the actual dimensions, i.e. the value in millimeters at the lesion's highest points. Percent change in height of all three target lesions were calculated and averaged for each participant. The average lesion height at baseline was calculated for each participant. An analysis of covariance (ANCOVA) was performed with average percentage change in target lesion height as the response variable, treatment group (3% BPO or vehicle) as a main effect, and average baseline target lesion height as a covariate. A greater reduction in the percentage change in height of the target lesions indicated a better outcome measure

    Time frame: Baseline to Day 4

Secondary outcomes

  1. To Assess the Percentage Change in Acne Lesion Swelling (Height) for the 3% Benzoyl Peroxide Gel Test Product and Positive Control Relative to the Vehicle Gel.

    The Investigator assessed and score each target lesion's swelling (elevation), elevation scores were the actual dimensions, i.e. the value in millimeters at the lesion's highest points. Percent change in height of all three target lesions were calculated and averaged for each participant. The average lesion height at baseline was calculated for each participant

    Time frame: Baseline to 2 hours, 4 hours, Day 1, Day 2 and Day 4

  2. To Assess the Change in Acne Lesion Redness (Erythema) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.

    The investigator assessed the erythema of the target lesion according to the following scale and tabulated the responses: 0=none, 1=minimal, 2=mild, 3=-moderate, 4=severe.

    Time frame: Baseline to 2 hours, 4 hours, Day 1, Day 2, and Day 4

  3. To Assess the Percentage Change in Acne Lesion Diameter (Size) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.

    The Investigator assessed and score each target lesion's diameter (size). Diameter scores were the actual dimensions, i.e. the value in millimeters at the lesion's widest or highest points.

    Time frame: Baseline to 2 hours, 4 hours, Day 1, Day 2, and Day 4

  4. To Assess the Change in Facial Skin Clarity for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel

    The Skin clarity was measured using the following scale; 0 Very Clear; 1 Clear; 2 Dull; 3 Very Dull; 4 Unclear. The responses were then tabulated

    Time frame: Baseline to 2 hours, 4 hours, Day 1, Day 2, and Day 4

  5. To Assess the Change in Perceptions of the Overall Appearance of Their Skin for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel

    The participants were asked to rate the overall appearance of their facial skin as; 1= Very Dissatisfied; 2= Slightly Dissatisfied; 3= Neither Satisfied nor Dissatisfied; 4= Slightly Satisfied; 5= Very Satisfied. The responses were then tabulated.

    Time frame: Baseline to 2 hours, 4 hours, Day 1, Day 2, and Day 4

07

Results

Posted May 18, 2015

Participant flow

Participants were recruited at a clinical site in USA

Participant flow — Overall Study
MilestoneTest ProductVehicle GelPositive Control
Started303030
Completed303030
Not completed000

Outcome measures

PrimaryTo Assess the Percentage Change in Acne Lesion Swelling (Height) of the Target Lesion for 3% Benzoyl Peroxide (BPO) Gel Test Product Relative to the Vehicle Gel After 4 Once-daily Applications.

The Investigator assessed and score each target lesion's swelling (elevation), elevation scores were the actual dimensions, i.e. the value in millimeters at the lesion's highest points. Percent change in height of all three target lesions were calculated and averaged for each participant. The average lesion height at baseline was calculated for each participant. An analysis of covariance (ANCOVA) was performed with average percentage change in target lesion height as the response variable, treatment group (3% BPO or vehicle) as a main effect, and average baseline target lesion height as a covariate. A greater reduction in the percentage change in height of the target lesions indicated a better outcome measure

Time frame:
Baseline to Day 4
Reported as:
Mean · Percentage change
To Assess the Percentage Change in Acne Lesion Swelling (Height) of the Target Lesion for 3% Benzoyl Peroxide (BPO) Gel Test Product Relative to the Vehicle Gel After 4 Once-daily Applications.
Percentage changeTest ProductVehicle GelPositive Control
To Assess the Percentage Change in Acne Lesion Swelling (Height) of the Target Lesion for 3% Benzoyl Peroxide (BPO) Gel Test Product Relative to the Vehicle Gel After 4 Once-daily Applications.-57.42 ± 6.229-47.89 ± 6.237-53.07 ± 6.233
Statistical analysis
  • Test Product vs Vehicle Gel · ANCOVA · p = 0.283
SecondaryTo Assess the Percentage Change in Acne Lesion Swelling (Height) for the 3% Benzoyl Peroxide Gel Test Product and Positive Control Relative to the Vehicle Gel.

The Investigator assessed and score each target lesion's swelling (elevation), elevation scores were the actual dimensions, i.e. the value in millimeters at the lesion's highest points. Percent change in height of all three target lesions were calculated and averaged for each participant. The average lesion height at baseline was calculated for each participant

Time frame:
Baseline to 2 hours, 4 hours, Day 1, Day 2 and Day 4
Reported as:
Mean · Percentage change
To Assess the Percentage Change in Acne Lesion Swelling (Height) for the 3% Benzoyl Peroxide Gel Test Product and Positive Control Relative to the Vehicle Gel.
Percentage changeTest ProductVehicle GelPositive Control
From baseline to hour 2-3.24 ± 8.726-4.65 ± 10.558-4.57 ± 10.754
From baseline to hour 4-6.02 ± 9.172-7.01 ± 11.525-5.94 ± 11.774
From baseline to day 1-21.42 ± 25.578-22.07 ± 19.688-20.22 ± 25.711
From baseline to day 2-40.30 ± 34.011-37.03 ± 28.968-42.94 ± 31.121
From baseline to day 4-57.22 ± 36.372-48.60 ± 34.585-52.57 ± 33.580
SecondaryTo Assess the Change in Acne Lesion Redness (Erythema) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.

The investigator assessed the erythema of the target lesion according to the following scale and tabulated the responses: 0=none, 1=minimal, 2=mild, 3=-moderate, 4=severe.

Time frame:
Baseline to 2 hours, 4 hours, Day 1, Day 2, and Day 4
Reported as:
Mean · Units on a scale
To Assess the Change in Acne Lesion Redness (Erythema) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.
Units on a scaleTest ProductVehicle GelPositive Control
Change from baseline to hour 2-0.04 ± 0.190-0.02 ± 0.122-0.03 ± 0.221
Change from baseline to hour 4-0.12 ± 0.283-0.06 ± 0.304-0.10 ± 0.279
Change from baseline to day 1-0.62 ± 0.811-0.56 ± 0.639-0.73 ± 0.851
Change from baseline to day 2-1.26 ± 1.225-1.02 ± 0.967-1.36 ± 1.168
Change from baseline to day 4-1.83 ± 1.228-1.39 ± 1.247-1.84 ± 1.303
SecondaryTo Assess the Percentage Change in Acne Lesion Diameter (Size) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.

The Investigator assessed and score each target lesion's diameter (size). Diameter scores were the actual dimensions, i.e. the value in millimeters at the lesion's widest or highest points.

Time frame:
Baseline to 2 hours, 4 hours, Day 1, Day 2, and Day 4
Reported as:
Mean · Percentage change
To Assess the Percentage Change in Acne Lesion Diameter (Size) for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel.
Percentage changeTest ProductVehicle GelPositive Control
From baseline to hour 2-0.46 ± 10.920-1.33 ± 7.274-0.33 ± 7.112
From baseline to hour 4-0.74 ± 9.397-0.22 ± 10.666-0.63 ± 9.244
From baseline to day 1-12.46 ± 27.993-12.83 ± 20.836-11.93 ± 22.049
From baseline to day 2-30.98 ± 38.935-29.81 ± 36.983-37.83 ± 32.315
From baseline to day 4-52.56 ± 39.058-38.78 ± 44.7000-44.78 ± 35.933
SecondaryTo Assess the Change in Facial Skin Clarity for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel

The Skin clarity was measured using the following scale; 0 Very Clear; 1 Clear; 2 Dull; 3 Very Dull; 4 Unclear. The responses were then tabulated

Time frame:
Baseline to 2 hours, 4 hours, Day 1, Day 2, and Day 4
Reported as:
Mean · Units on a scale
To Assess the Change in Facial Skin Clarity for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel
Units on a scaleTest ProductVehicle GelPositive Control
Baseline to hour 20.0 ± 0.000.0 ± 0.000.0 ± 0.00
Baseline to hour 40.0 ± 0.000.0 ± 0.000.0 ± 0.00
Baseline to day 1-0.2 ± 0.43-0.2 ± 0.38-0.3 ± 0.48
Baseline to day 2-0.8 ± 0.81-0.5 ± 0.51-0.7 ± 0.84
Baseline to day 4-1.2 ± 0.90-0.7 ± 0.79-1.0 ± 0.98
SecondaryTo Assess the Change in Perceptions of the Overall Appearance of Their Skin for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel

The participants were asked to rate the overall appearance of their facial skin as; 1= Very Dissatisfied; 2= Slightly Dissatisfied; 3= Neither Satisfied nor Dissatisfied; 4= Slightly Satisfied; 5= Very Satisfied. The responses were then tabulated.

Time frame:
Baseline to 2 hours, 4 hours, Day 1, Day 2, and Day 4
Reported as:
Mean · Units on a scale
To Assess the Change in Perceptions of the Overall Appearance of Their Skin for the 3% BPO Gel Test Product and Positive Control Relative to the Vehicle Gel
Units on a scaleTest ProductVehicle GelPositive Control
Change from baseline to hour 20.3 ± 0.840.1 ± 0.820.3 ± 0.71
Change from baseline to hour 40.4 ± 0.930.3 ± 0.990.4 ± 1.07
Change from baseline to day 10.3 ± 0.920.3 ± 1.030.4 ± 1.13
Change from baseline to day 20.5 ± 1.140.6 ± 1.030.7 ± 1.24
Change from baseline to day 40.9 ± 1.030.8 ± 1.300.8 ± 1.32

Adverse events

Collected over 5 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Product—0/30 (0%)0/30 (0%)
Vehicle Gel—0/30 (0%)0/30 (0%)
Positive Control—0/30 (0%)0/30 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Test ProductVehicle GelPositive ControlTotal
Mean22.1 ± 9.9020.3 ± 7.4717.8 ± 6.2220.1 ± 8.11
Sex: Female, Male
Sex: Female, Male(Participants)Test ProductVehicle GelPositive ControlTotal
Female18 ± 60.017 ± 56.712 ± 40.047
Male12 ± 40.013 ± 43.318 ± 60.043
08

Study locations

1 site
  • GSK Investigational Site
    High Point, North Carolina 27262, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in May 2015, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2014
First posted
Feb 3, 2014
Start
Feb 2014
Primary completionActual
May 2014
CompletionActual
May 2014
Results first posted
May 18, 2015
Last update
May 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02052752
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 3, 2014
Start date
Feb 2014
Primary completion
May 2014
Completion
May 2014
Results posted
May 18, 2015
Last update
May 18, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benzoyl Peroxide

Start the discussion